This article looks at the 14 Best Multibagger Penny Stocks to Buy Right Now.The Russell 2000 Index has hit fresh highs heading into 2026, signaling renewed interest in small companies. The index is already up by more than 13% for the year as market rotation from large-cap stocks gathers pace.The renewed focus on penny and small-cap stocks comes as investors rotate into higher-risk, higher-reward assets. The shift also underscores growing confidence in the broader economy and corporate sector, as they are ex ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Snowflake Inc (NYSE:SNOW) fell sharply in pre-market trading after posting quarterly results.Snowflake delivered third-quarter revenue of $1.21 billion, beating analyst estimates of $1.18 billion, according to Benzinga Pro. The AI data cloud company reported adjusted earnings of 35 cents per share for the period, beating analyst estimates of 31 cents per share.Snowflake shares dipped 8.6% to $241.85 in ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 250 points on Wednesday.The Dow traded up 0.61% to 47,765.87 while the NASDAQ rose 0.07% to 23,430.56. The S&P 500 also rose, gaining, 0.22% to 6,844.57.Check This Out: How To Earn $500 A Month From Dollar General Stock Ahead Of Q3 EarningsLeading and Lagging SectorsEnergy shares jumped by 1.2% on Wednesday.In trading on Wednesday, information technology stocks fell by 0.6%.Top HeadlineMacy's Inc (NYSE:M) posted better-th ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - ADC Therapeutics SA has announced updated results from the LOTIS-7 clinical trial, highlighting the potential of ZYNLONTA in treating DLBCL (Diffuse Large B-cell Lymphoma) [2][3]. Group 1: Clinical Trial Update - The LOTIS-7 clinical trial results were shared in a press release and are available on the company's website [2]. - The Chief Medical Officer, Mohamed Zaki, will provide detailed insights into the LOTIS-7 clinical trial and its updated results during the call [3]. Group 2: Strategic Overview - Ameet Mallik, the Chief Executive Officer, will present a strategic overview and discuss the opportunity for ZYNLONTA in the DLBCL market [3].

Summary of ADC Therapeutics SA Lotus 7 Update Conference Call Company and Industry Overview - **Company**: ADC Therapeutics SA - **Industry**: Oncology, specifically focusing on therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Key Points and Arguments 1. **Clinical Trial Update**: ADC Therapeutics announced updated results from the LOTIS-7 clinical trial, focusing on the combination of Zynlonta and glofitamab for treating DLBCL [2][10] 2. **Zynlonta's Profile**: Zynlonta is positioned as a single-agent therapy for third-line plus DLBCL, with rapid, deep, and durable efficacy, and manageable safety [4][20] 3. **Market Opportunity**: The potential peak revenue for Zynlonta in DLBCL is estimated to be between $500 million and $800 million, with a broader potential reaching $600 million to $1 billion as it expands into earlier lines of therapy and indolent lymphomas [20][21] 4. **Efficacy Data**: The best overall response rate (ORR) in the LOTIS-7 trial was reported at 89.8%, with a complete response (CR) rate of 77.6% among 49 efficacy-available patients [11][12] 5. **Patient Demographics**: The median age of patients in the study was 70 years, with a range from 26 to 85 years, and a median of one prior line of therapy [12][14] 6. **Safety Profile**: Neutropenia was the most common treatment-emergent adverse event, occurring in 32.7% of patients, consistent with known profiles of the individual drugs [11][14][39] 7. **Combination Therapy Rationale**: The combination of Zynlonta and glofitamab is expected to provide additive or synergistic efficacy due to their complementary mechanisms of action [8][10] 8. **Regulatory Strategy**: ADC Therapeutics plans to submit for regulatory approval and compendia listing following positive results from ongoing trials, with updates expected in 2026 [22][23] Additional Important Information 1. **Treatment Landscape**: The DLBCL treatment landscape is evolving, with a current 60/40 split between complex therapies (e.g., CAR-T, bispecifics) and broadly accessible therapies (e.g., ADCs, monoclonal antibodies) [5][6] 2. **Future Catalysts**: Multiple data catalysts are expected in 2026, including updates from LOTIS-5 and LOTIS-7 trials, which could significantly impact Zynlonta's market potential [21][22] 3. **Durability of Responses**: Among patients achieving CR, 33 out of 38 maintained their response as of the data cutoff, indicating promising durability [11][19] 4. **Comparative Efficacy**: The trial showed strong efficacy in both relapsed (100% ORR, 91.6% CR) and primary refractory (80% ORR, 64% CR) patient populations [18][30] 5. **Enrollment Trajectory**: The company is on track to complete enrollment of 100 patients in the LOTIS-7 trial by the first half of 2026, with a focus on maintaining a balanced patient population [43] This summary encapsulates the critical insights from the ADC Therapeutics conference call, highlighting the company's strategic direction, clinical trial outcomes, and market potential in the oncology sector.

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

Core Insights - ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA® combined with glofitamab (COLUMVI®) achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) [1][2] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs), focusing on innovative treatments for patients with hematological malignancies [2] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [2] Clinical Trial Highlights - The LOTIS-7 trial is designed to evaluate the safety and efficacy of ZYNLONTA in combination with various agents, including glofitamab, in patients with B-cell non-Hodgkin lymphoma [1] - As of November 17, 2025, 49 patients were efficacy-evaluable, with a minimum of 6 months follow-up [1] - The trial aims to complete enrollment of approximately 100 patients by the first half of 2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026 [1] Efficacy Data - The best overall response rate (ORR) was 89.8%, with 44 out of 49 patients responding [1] - The complete response (CR) rate was 77.6%, with 33 of the 38 patients who achieved CR remaining in that state at the data cutoff [1] - In the subgroup of 24 relapsed patients, the ORR was 100% and the CR rate was 91.7% [1] - Among 25 primary refractory patients, the ORR was 80% and the CR rate was 64% [1] Safety Profile - The combination treatment was generally well tolerated, with a manageable safety profile [1] - Grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%) [1] - Cytokine release syndrome (CRS) occurred in 36.7% of patients, with varying severity across dose levels [1] Future Plans - The company plans to assess regulatory and compendia strategies for ZYNLONTA and its combinations [1] - ADC Therapeutics is also advancing a next-generation PSMA-targeting ADC, leveraging its expertise in ADC development [2]

Summary of ADC Therapeutics Conference Call Company Overview - ADC Therapeutics is focused on antibody-drug conjugates (ADCs) and is a commercial-stage company with an approved product, Zynlonta, for third-line treatment of diffuse large B-cell lymphoma (DLBCL) [5][6][20] Market Performance - Zynlonta has maintained a stable market share of approximately 10% in the third-line DLBCL setting despite competition from bispecific therapies, which have gained significant market share [7][20] - The DLBCL market is divided into complex therapies (CAR-T and bispecifics) and broadly accessible therapies (ADCs, monoclonal antibodies, and chemotherapy) [6][10] Clinical Trials and Studies - **LOTIS-5 Trial**: A confirmatory study comparing Zynlonta plus rituximab to R-GemOx, with a primary endpoint of progression-free survival (PFS). Top-line results are expected in the first half of 2026 [11][12][20] - **LOTIS-7 Trial**: A study combining Zynlonta with glofitamab, showing promising initial results with an overall response rate of 93% and a complete response (CR) rate of 87% [31][35] Market Opportunities - The third-line DLBCL setting has about 6,000 patients, which could double to over 12,000 in the second-line setting. The potential market opportunity for LOTIS-5 is estimated at $200 million to $300 million [20][21] - The marginal zone lymphoma market presents a significant opportunity with an estimated market potential of $500 million, given the high unmet need and competitive CR rates [24][25] Safety and Efficacy - Zynlonta is characterized by a favorable safety profile, being a fixed-duration, chemo-free therapy with manageable and reversible side effects [18][19] - The company aims to achieve a CR rate of 40% or higher in combination therapies to differentiate itself in the market [16] Financial Position - As of Q3, ADC Therapeutics reported a pro forma cash position of $293 million, providing a runway into at least 2028, which supports the relaunch of Zynlonta and ongoing clinical trials [40] Future Outlook - The company is exploring additional indications for Zynlonta and has a PSMA-directed ADC that is expected to be IND-ready by the end of the year, with plans to seek partnerships for this asset [39] Conclusion - ADC Therapeutics is strategically positioned in the ADC market with a focus on expanding the use of Zynlonta through ongoing clinical trials and exploring new indications, while maintaining a strong financial position to support its growth initiatives [38][40]